Ascendis Pharma (A1SN34) Stock Overview

Operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. More details

A1SN34 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	2/6
Financial Health	2/6
Dividends	0/6

Rewards

Trading at 48.3% below our estimate of its fair value

Earnings are forecast to grow 16.63% per year

Became profitable this year

Risk Analysis

High level of non-cash earnings

Shares are highly illiquid

A1SN34 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW491,361 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

491,361 investors already sharing narratives

View all narratives

Ascendis Pharma A/S Competitors

Price History & Performance

Summary of share price highs, lows and changes for Ascendis Pharma
Historical stock prices
Current Share Price	US$87.30
52 Week High	US$94.05
52 Week Low	US$66.64
Beta	0
1 Month Change	-2.61%
3 Month Change	n/a
1 Year Change	41.67%
3 Year Change	199.18%
5 Year Change	n/a
Change since IPO	146.96%

Recent updates

Shareholder Returns

	A1SN34	BR Biotechs	BR Market
7D	-5.3%	0.1%	-0.9%
1Y	41.7%	14.7%	18.3%

Return vs Industry: A1SN34 exceeded the BR Biotechs industry which returned 14.3% over the past year.

Return vs Market: A1SN34 exceeded the BR Market which returned 18.8% over the past year.

Price Volatility

Is A1SN34's price volatile compared to industry and market?
A1SN34 volatility
A1SN34 Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.3%
Market Average Movement	4.5%
10% most volatile stocks in BR Market	7.9%
10% least volatile stocks in BR Market	2.0%

Stable Share Price: A1SN34's share price has been volatile over the past 3 months compared to the BR market.

Volatility Over Time: Insufficient data to determine A1SN34's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2006	1,189	Jan Mikkelsen	ascendispharma.com

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

Ascendis Pharma A/S Fundamentals Summary

How do Ascendis Pharma's earnings and revenue compare to its market cap?
A1SN34 fundamental statistics
Market cap	R$85.96b
Earnings (TTM)	R$2.90b
Revenue (TTM)	R$5.05b

29.7x

P/E Ratio

17.0x

P/S Ratio

Is A1SN34 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A1SN34 income statement (TTM)
Revenue	€865.78m
Cost of Revenue	€94.91m
Gross Profit	€770.87m
Other Expenses	€274.94m
Earnings	€495.93m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	7.52
Gross Margin	89.04%
Net Profit Margin	57.28%
Debt/Equity Ratio	152.9%

How did A1SN34 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/29 16:02
End of Day Share Price	2026/07/27 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ascendis Pharma A/S is covered by 30 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Eliana Merle	Barclays
Tazeen Ahmad	BofA Global Research
Michelle Gilson	Canaccord Genuity

Ascendis Pharma (A1SN34) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Ascendis Pharma A/S Competitors

Blau Farmacêutica

Biomm

PharmaEssentia

Innovent Biologics

Price History & Performance

Recent News & Updates

Ascendis Pharma A/S Announces New Radiographic Data from Week 104 of the Completed Pivotal Approach Trial of Once-Weekly Transcon Cnp in Children with Achondroplasia

Ascendis Pharma Reports Week 182 Data From Phase 3 PaTHway Trial Demonstrating Sustained Efficacy And Safety Of TransCon PTH In Adults With Hypoparathyroidism

Ascendis Pharma A/S Announces 5-Year Phase 2 Data Show TransCon PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

Ascendis Pharma A/S Announces New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged =5 Years

Ascendis Pharma A/S to Report Q1, 2026 Results on May 07, 2026

Ascendis Pharma A/S(NasdaqGS:ASND) dropped from NASDAQ Composite Index

Recent updates

Ascendis Pharma A/S Announces New Radiographic Data from Week 104 of the Completed Pivotal Approach Trial of Once-Weekly Transcon Cnp in Children with Achondroplasia

Ascendis Pharma Reports Week 182 Data From Phase 3 PaTHway Trial Demonstrating Sustained Efficacy And Safety Of TransCon PTH In Adults With Hypoparathyroidism

Ascendis Pharma A/S Announces 5-Year Phase 2 Data Show TransCon PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

Ascendis Pharma A/S Announces New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged =5 Years

Ascendis Pharma A/S to Report Q1, 2026 Results on May 07, 2026

Ascendis Pharma A/S(NasdaqGS:ASND) dropped from NASDAQ Composite Index

Ascendis Pharma A/S Announces New Data from Ongoing Coach Trial Demonstrating Transcon hGH Accelerates Transcon CNP’S Benefits Beyond Linear Growth in Children with Achondroplasia

Ascendis Pharma A/S Launches YUVIWEL (Navepegritide) In The United States

Ascendis Pharma A/S Elects Jean-Jacques Bienaimé as New Non-Executive Member of the Board

Ascendis Pharma A/S Reports New Insights Trial Results For TransCon HGH In Turner Syndrome

Ascendis Pharma Announces Durable Benefits of Transcon Cnp in Children with Achondroplasia

Ascendis Pharma A/S Announces FDA Approves Once-Weekly YUVIWEL®? (Navepegritide) for Children with Achondroplasia Aged 2 Years and Older

Ascendis Pharma A/S, Annual General Meeting, Mar 23, 2026

Ascendis Pharma A/S to Report Fiscal Year 2025 Results on Feb 11, 2026

Ascendis Pharma A/S Announces Topline Results from Week 52 of COACH Trial Evaluating Combination Therapy in Children with Achondroplasia

Ascendis Pharma A/S Announces Results of Pivotal Approach Trial of Transcon CNP (Navepegritide) in Children with Achondroplasia Published in Jama Pediatrics

Ascendis Pharma A/S Announces New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon®? PTH (Palopegteriparatide)Treated Adults with Hypoparathyroidism

Ascendis Pharma A/S to Report Q3, 2025 Results on Nov 12, 2025

Ascendis Pharma A/S Submits Marketing Authorisation Application to the European Medicines Agency for TransCon CNP

Ascendis Pharma A/S to Report Q2, 2025 Results on Aug 07, 2025

FDA Approves SKYTROFA (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency

Ascendis Pharma A/S Announces New Data from Week 156 of its Phase 3 PaTHway Trial Confirms Sustained Response to TransCon PTH Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life

Ascendis Pharma A/S to Share Its Latest Endocrinology Rare Disease Data At Endo 2025

Ascendis Pharma A/S Announces Week 26 Interim Analysis Results from Its Ongoing Coach Trial

Ascendis Pharma A/S Announces Fda Acceptance of Transcon®? Cnp Nda for Priority Review

Ascendis Pharma A/S Announces New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon CNP (navepegritide)

Ascendis Pharma A/S Announces New 4-Year Data Shows Sustained Response to TransCon PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

Ascendis Pharma A/S to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

Ascendis Pharma A/S, Annual General Meeting, May 27, 2025

Ascendis Pharma A/S to Report Q1, 2025 Results on May 01, 2025

Ascendis Pharma A/S Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

Ascendis Pharma A/S (NasdaqGS:ASND) announces an Equity Buyback for $18.25 million worth of its shares.

Ascendis Pharma A/S to Report Fiscal Year 2024 Results on Feb 12, 2025

BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court

Ascendis Pharma A/S Announces Positive Week 26 Topline Results from New Insights

Ascendis Pharma A/S Announces U.S. Food & Drug Administration Accepts for Supplemental Biologics License Application for TransCon HGH for Adult GHD

Ascendis Pharma A/S to Report Q3, 2024 Results on Nov 14, 2024

Ascendis Pharma A/S Announces Submission of Supplemental Biologics License Application to FDA for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency

Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $300 million.

Ascendis Pharma A/S Announces Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (Proc) Cohort of the Phase 1/2 Il-Believe Trial At Esmo 2024

Ascendis Pharma A/S to Report Q2, 2024 Results on Sep 03, 2024

Ascendis Pharma A/S Announces Food & Drug Administration Approves Yorvipath® (Palopegteriparatide; Developed as Transcon Pth) for the Treatment of Hypoparathyroidism in Adults

Ascendis Pharma A/S Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism

Ascendis Pharma A/S Announces 2-Year Results from A Post-Hoc Analysis of the Company's Phase 3 PaTHway Trial

Ascendis Pharma A/S, Annual General Meeting, May 30, 2024

Ascendis Pharma A/S to Report Q1, 2024 Results on May 02, 2024

Ascendis Pharma A/S Announces United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer

Ascendis Pharma A/S to Report Fiscal Year 2023 Results on Feb 07, 2024

Ascendis Pharma A/S Introduces Vision 2030

Ascendis Pharma A/S Announces New Analyses from Blinded and Ongoing Open-Label Extension Portions of ACcomplisH

Ascarma A/S Announces TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency

FDA Accepts for Review Resubmitted NDA for Transcon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism

Ascendis Pharma A/S Announces European Commission Approval of YORVIPATH (Palopegteriparatide) for Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Resubmits NDA for TransCon™? PTH to the U.S. FDA

Ascendis Presents Updated and New Transco Il-2 ß/? Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types At Esmo 2023

Ascendis Pharma A/S Presents Transcon Pth Data At the American Thyroid Association Annual Meeting

Ascendis Pharma A/S Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency

Ascendis Pharma Launches SKYTROFA (Lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency

Ascendis Pharma A/S Receives Positive CHMP Opinion for Transcon PTH (Palopegteriparatide) for Adults with Chronic Hypoparathyroidism